GWG Holdings Announces Special Cash Dividend
Feb 09, 2017 21:10 pm UTC| Business
MINNEAPOLIS, Feb. 09, 2017 -- GWG Holdings, Inc. (Nasdaq:GWGH), a financial services company committed to transforming the life insurance industry, announced that its board of directors has approved the payment of a...
GWG Holdings Announces Special Cash Dividend
Feb 09, 2017 21:10 pm UTC| Business
MINNEAPOLIS, Feb. 09, 2017 -- GWG Holdings, Inc. (Nasdaq:GWGH), a financial services company committed to transforming the life insurance industry, announced that its board of directors has approved the payment of a...
Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017
Feb 09, 2017 21:10 pm UTC| Business
U.S. Product Revenue up 65%, Driven by Growth in U.S. Dermatology SalesCash Position of $20.5 Million; More Than Fully Funded to Achieve EBITDA Breakeven Income From Discontinued Operations of $15.5 Million and Net Income...
Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017
Feb 09, 2017 21:10 pm UTC| Business
U.S. Product Revenue up 65%, Driven by Growth in U.S. Dermatology SalesCash Position of $20.5 Million; More Than Fully Funded to Achieve EBITDA Breakeven Income From Discontinued Operations of $15.5 Million and Net Income...
Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017
Feb 09, 2017 21:10 pm UTC| Business
U.S. Product Revenue up 65%, Driven by Growth in U.S. Dermatology SalesCash Position of $20.5 Million; More Than Fully Funded to Achieve EBITDA Breakeven Income From Discontinued Operations of $15.5 Million and Net Income...
Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017
Feb 09, 2017 21:10 pm UTC| Business
U.S. Product Revenue up 65%, Driven by Growth in U.S. Dermatology SalesCash Position of $20.5 Million; More Than Fully Funded to Achieve EBITDA Breakeven Income From Discontinued Operations of $15.5 Million and Net Income...
Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017
Feb 09, 2017 21:10 pm UTC| Business
U.S. Product Revenue up 65%, Driven by Growth in U.S. Dermatology SalesCash Position of $20.5 Million; More Than Fully Funded to Achieve EBITDA Breakeven Income From Discontinued Operations of $15.5 Million and Net Income...